

19<sup>th</sup> June 2024

**VENTURE LIFE GROUP PLC**

("Venture Life", "VLG" or the "Group")

**Posting of Annual Report**

Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, announces that the Company's Annual Report and Accounts for the year ended 31 December 2023 are available to be viewed on the Venture Life website: [www.venture-life.com](http://www.venture-life.com), and that copies have been sent to shareholders.

**For further information, please contact:**

**Venture Life Group PLC**

+44 (0) 1344 578004

Jerry Randall, Chief Executive Officer  
Daniel Wells, Chief Financial Officer

**Cavendish Capital Markets Limited (Nomad and Broker)**

+44 (0) 20 7720 0500

Stephen Keys/Camilla Hume (Corporate Finance)  
Michael Johnson (Sales)

**About Venture Life ([www.venture-life.com](http://www.venture-life.com))**

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, and Sweden, the Group's product portfolio includes some key products such as the Balance Active range in the area of women's intimate healthcare, the Earol® product line in ENT care, the Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, the UltraDEX and Dentyl oral care product ranges, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. Its products are sold in over 90 countries worldwide.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.

Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ACSQKCBQNBKDBAD